Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study
Published Jul 10, 2010 · B. Zinman, S. Harris, J. Neuman
The Lancet
142
Citations
3
Influential Citations
Abstract
Abstract removed due to Elsevier request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Study Snapshot
Key takeawayLow-dose combination therapy with rosiglitazone and metformin significantly reduces the risk of developing type 2 diabetes by 66% and 26%, with no significant change in insulin sensitivity.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.